Table 2 Renal outcomes
From: Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
Biologics compared to placebo for the treatment of Systemic Lupus Erythematosus measured by renal outcomes | |||||
|---|---|---|---|---|---|
Patient or population: Systemic Lupus Erythematosus Setting: Inpatients then outpatients Intervention: Biologics Comparison: Standard of care, placebo | |||||
Outcomes | № of participants (studies) Follow-up | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
Risk with placebo | Risk difference with Renal outcomes | ||||
Partial and/or complete renal response by 1 year—Abatacept | 377 (2 RCTs) | ⨁⨁◯◯ Lowa,b,c,d | RR 0.98 (0.78 to 1.23) | 436 per 1,000 | 9 fewer per 1,000 (96 fewer to 100 more) |
Partial and/or complete renal response by 1 year—Belimumab | 43 (1 RCT) | ⨁◯◯◯ Very lowc,d,e | RR 1.28 (0.67 to 2.45) | 409 per 1,000 | 115 more per 1,000 (135 fewer to 593 more) |
Partial and/or complete renal response by 1 year—Obinutuzumab | 125 (1 RCT) | ⨁⨁⨁◯ Moderated | RR 1.60 (1.27 to 2.02) | 565 per 1,000 | 339 more per 1,000 (152 more to 576 more) |
Partial and/or complete renal response by 1 year—Ocrelizumab | 223 (1 RCT) | ⨁⨁◯◯ Lowa,b,d,f | RR 1.22 (0.97 to 1.55) | 547 per 1,000 | 120 more per 1,000 (16 fewer to 301 more) |
Partial and/or complete renal response by 1 year—Rituximab | 144 (1 RCT) | ⨁⨁⨁◯ Moderatea,b,d | RR 1.24 (0.90 to 1.71) | 458 per 1,000 | 110 more per 1,000 (46 fewer to 325 more) |
Partial and/or complete renal response by 2 years—Belimumab | 488 (2 RCTs) | ⨁◯◯◯ Very lowd,g,h | RR 1.28 (1.03 to 1.58) | 361 per 1,000 | 101 more per 1,000 (11 more to 209 more) |
Partial and/or complete renal response by 2 years—Obinituzumab | 125 (1 RCT) | ⨁⨁⨁◯ Moderatec,d | RR 1.83 (1.06 to 3.16) | 226 per 1,000 | 187 more per 1,000 (14 more to 488 more) |